BofA analyst Geoff Meacham lowered the firm’s price target on Caribou Biosciences to $25 from $27 and keeps a Buy rating on the shares post the Q4 results. The analyst cites the company’s updated cash position and increased uncertainty of its early pipeline in current macroenvironment for the target drop.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRBU:
- Caribou Biosciences price target lowered to $26 from $27 at H.C. Wainwright
- Caribou Biosciences price target lowered to $32 from $36 at Oppenheimer
- Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Caribou Biosciences reports Q4 EPS (44c), consensus (46c)
- Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
